Cancer Genetics (NASDAQ:CGIX) Trading Down 6%

Cancer Genetics Inc (NASDAQ:CGIX) shares dropped 6% on Thursday . The company traded as low as $0.17 and last traded at $0.18, approximately 966,695 shares were traded during trading. A decline of 45% from the average daily volume of 1,767,514 shares. The stock had previously closed at $0.19.

The company has a current ratio of 0.36, a quick ratio of 0.36 and a debt-to-equity ratio of 0.24. The firm’s 50 day simple moving average is $0.17. The stock has a market cap of $10.99 million, a P/E ratio of -0.27 and a beta of 1.48.

Cancer Genetics (NASDAQ:CGIX) last released its earnings results on Monday, May 20th. The medical research company reported ($0.08) earnings per share for the quarter. Cancer Genetics had a negative net margin of 77.28% and a negative return on equity of 175.72%. The firm had revenue of $6.84 million for the quarter.

Several institutional investors and hedge funds have recently added to or reduced their stakes in CGIX. Geode Capital Management LLC increased its stake in shares of Cancer Genetics by 106.6% in the 4th quarter. Geode Capital Management LLC now owns 221,803 shares of the medical research company’s stock valued at $53,000 after purchasing an additional 114,448 shares during the last quarter. Virtu Financial LLC bought a new position in shares of Cancer Genetics in the 1st quarter valued at $48,000. Finally, Perkins Capital Management Inc. increased its stake in shares of Cancer Genetics by 649.9% in the 1st quarter. Perkins Capital Management Inc. now owns 3,136,528 shares of the medical research company’s stock valued at $753,000 after purchasing an additional 2,718,278 shares during the last quarter. Institutional investors own 10.60% of the company’s stock.

About Cancer Genetics (NASDAQ:CGIX)

Cancer Genetics, Inc develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, Europe, and Asia. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology and immuno-oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.

Further Reading: What Are Cryptocurrencies?

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.